The U.S. Food and Drug Administration has granted priority review to giredestrant, an investigational oral therapy for adults with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. This designation means the FDA will aim to complete its review within six months instead of the standard ten, reflecting the agency’s belief that the drug could offer a significant improvement over existing treatments. According to a report from Targeted Oncology, the decision is based on data from a pivotal clinical trial.

Key Takeaways

  • Giredestrant is an oral selective estrogen receptor degrader (SERD) being developed for ER+/HER2- breast cancer.
  • The FDA has granted priority review, accelerating the standard review timeline to six months.
  • The drug targets advanced or metastatic disease in patients who have progressed on prior endocrine therapy.
  • Priority review does not guarantee eventual approval; the FDA will assess safety and efficacy data.
  • If approved, giredestrant would offer an oral alternative to injectable SERDs such as fulvestrant.

What Is Giredestrant?

Giredestrant is an oral selective estrogen receptor degrader (SERD) under investigation for the treatment of estrogen receptor-positive (ER+) breast cancer. Unlike traditional endocrine therapies that block estrogen production or bind to the receptor, SERDs work by both blocking the receptor and causing its degradation. Giredestrant is designed to be taken by mouth, which may offer convenience compared with injectable SERDs like fulvestrant, the only currently approved SERD for advanced breast cancer.

The drug has been studied in several clinical trials, including the phase 3 ACELERA trial and earlier phase 1/2 studies. The original report from Targeted Oncology notes that the FDA’s priority review is based on results from a trial evaluating giredestrant in patients with ER+/HER2- advanced breast cancer who had previously received endocrine therapy.

What Does FDA Priority Review Mean?

Priority review is a designation the FDA uses to expedite the review of drugs that may represent a significant improvement over available therapies in terms of safety, efficacy, or convenience. When a drug receives priority review, the FDA aims to make a decision within six months of receiving the complete application, compared with the standard ten-month timeline. This does not guarantee approval, but it signals that the agency considers the drug a potential advance for a serious condition.

For giredestrant, the priority review reflects the unmet need for additional oral treatment options in ER+/HER2- breast cancer. Many patients with advanced disease eventually become resistant to standard endocrine therapies, and new agents that can overcome resistance are urgently needed.

Who Is This Treatment For?

The priority review applies to adult patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. This is the most common subtype of breast cancer, accounting for about 70% of all cases. Giredestrant is specifically targeting patients whose disease has progressed after prior endocrine therapy, such as aromatase inhibitors or tamoxifen, often in combination with a CDK4/6 inhibitor.

The clinical trial that supported the application included patients who had received at least one prior line of endocrine therapy. The exact details of the efficacy and safety results have not been fully disclosed in the brief news report, but the FDA’s decision to grant priority review suggests that the data were sufficiently promising.

Potential Impact on Breast Cancer Treatment

If approved, giredestrant would become the second FDA-approved oral SERD for advanced breast cancer, following elacestrant, which received approval in 2023. The availability of multiple oral SERDs could provide more options for patients who cannot tolerate or prefer to avoid injections. Oral administration is generally more convenient and may improve medication adherence.

The original report from Targeted Oncology emphasizes that the priority review is an important regulatory milestone for giredestrant. The FDA’s decision is expected within the next six months. Until then, patients with ER+/HER2- breast cancer should continue to discuss all available treatment options with their healthcare team, including clinical trials for investigational therapies.

Frequently Asked Questions

What is the difference between giredestrant and fulvestrant?

Both drugs are SERDs, meaning they degrade the estrogen receptor to stop cancer growth. The main difference is that fulvestrant is given as an intramuscular injection, typically every two weeks or monthly, while giredestrant is an oral tablet taken daily. Oral administration offers greater convenience and avoids injection-site reactions.

How long will the FDA review take?

Because giredestrant received priority review, the FDA aims to complete its evaluation within six months of accepting the application. The exact date of the decision will depend on when the application was formally accepted. According to the original report, the target action date is typically six months from the filing date.

Does priority review mean the drug will be approved?

No. Priority review indicates that the FDA believes the drug may offer a significant improvement over existing treatments, but it does not guarantee approval. The agency will still review all clinical data for safety and efficacy before making a final decision. It is possible that the FDA could request additional studies or deny the application.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.